Lupin Acquires Gavis for $880M to Bolster U.S. Generics Presence

Indian generics maker Lupin is set to buy privately held U.S. generics maker Gavis Pharmaceuticals for $880 million, a move that expands Lupin’s share of the U.S. generics market.

The deal will broaden Lupin’s portfolio to include more dermatology and controlled substance products. It also gives Lupin — India’s third-largest generics maker — its first real foothold in the U.S., with Gavis’ 45,000-square-foot Somerset N.J., manufacturing facility.

Lupin also operates an inhalation R&D center in Coral Springs, Fla., which will benefit from Gavis’ research and development team.

Gavis has 25 products on the market, 66 ANDAs pending approval with the FDA and more than 65 products in development. Lupin gave no timeline for closing the deal.

Last week, the company also purchased 13 central nervous system and rare disease drugs from German drugmaker Temmler Pharma to expand its reach into that country. Other recent acquisitions include Russian drugmaker Biocom earlier this month and Brazilian generics maker Medquimica in May — deals that expand Lupin’s presence into the 10th and sixth largest global pharmaceutical markets, respectively. — Kellen Owings